Artificial Intelligence Used in Screening Adrenal Nodules

September 27, 2025 updated by: Peking University First Hospital

The Application of Artificial Intelligence in Screening Adrenal Nodules in Low-dose Chest CT

By collecting chest low-dose spiral CT plain scan images, extracting effective features from the adrenal gland regions, training and validating an artificial intelligence-based automatic diagnostic algorithm for adrenal nodules, we will ultimately develop an artificial intelligence software with independent intellectual property rights that is specifically designed for screening adrenal nodules in chest low-dose CT scans.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
      • Beijing, China
        • Recruiting
        • Peking University First Hospital
        • Contact:
          • Peking University First Hospital
          • Phone Number: +86 66119025

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

The study population consists of individuals aged over 18 years, with no gender restrictions, who underwent chest low-dose CT scans as part of routine physical examinations. Notably, those with a history of malignant tumors are excluded, and only individuals with qualified imaging data (free from poor quality, artifacts, or other issues that hinder analysis) are included.

Description

Inclusion Criteria:

  1. The age of the population is over 18 years old, regardless of gender;
  2. Images from chest low-dose CT plain scan during routine physical examination;

Exclusion Criteria:

  1. Patients with a history of malignant tumors;
  2. Imaging images with poor quality, artifacts, etc., which make analysis impossible.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Nodular adrenal glands
Adrenal region segmentation and adrenal nodule identification in chest CT via artificial intelligence
Other: None intervention
this study is retrospective based on the CT images, which dose include any intervention.
Normal adrenal glands
Adrenal region delineation and adrenal gland identification in chest CT using artificial intelligence
Other: None intervention
this study is retrospective based on the CT images, which dose include any intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Overall Diagnostic Accuracy
Time Frame: From enrollment to the end of collection in one and a half years
From enrollment to the end of collection in one and a half years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Peking University First Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2025

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

January 30, 2027

Study Registration Dates

First Submitted

August 25, 2025

First Submitted That Met QC Criteria

September 27, 2025

First Posted (Estimated)

September 30, 2025

Study Record Updates

Last Update Posted (Estimated)

September 30, 2025

Last Update Submitted That Met QC Criteria

September 27, 2025

Last Verified

September 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022yan068-002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Adrenal Incidentalomas

Clinical Trials on None intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe